Meeting
2023 ASCO Annual Meeting
Association of a high E2F targets score with survival in hepatocellular carcinoma patients.
Authors
Kohei Chida
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Kohei Chida , Masanori Oshi , Arya Mariam Roy , Takafumi Yachi , Masaki Nara , Kyogo Yamada , Osamu Matsuura , Tadashi Hashizume , Itaru Endo , Kazuaki Takabe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4106)
DOI
10.1200/JCO.2023.41.16_suppl.4106
Abstract #
4106
Poster Bd #
427
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.
First Author: Brian Warnecke
Poster
2018 ASCO Annual Meeting
Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).
First Author: Lee Chun Park
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A decade of chemotherapy management in hepatocellular carcinoma: A single-center study in Latin America.
First Author: Wagner Eduardo Cruz Diaz